EOM Pharmaceuticals Holdings, Inc. (IMUC)

Market Cap	20.11M +5.1%
Revenue (ttm)	n/a
Net Income	-5.13M
EPS	-0.05
Shares Out	126.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7,889
Open	0.1590
Previous Close	0.1600
Day's Range	0.1590 - 0.1590
52-Week Range	0.0360 - 0.3399
Beta	1.29
RSI	48.16
Earnings Date	n/a

About IMUC

EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: IMUC